{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-22-000308","form_type":"8-K","ticker":"STEX","cik":"0001530766","company_name":"Streamex Corp.","filed_at":"2022-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.880234+00:00","generated_at":"2026-06-26T20:55:40.837142+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioSig appoints John Sieckhaus as COO; brings 30 years healthcare experience","bullets":["John Sieckhaus appointed COO effective March 21, 2022; base salary $280,000, annual bonus eligible.","Received signing bonus of 50,000 fully vested shares plus options for 350,000 shares vesting over 3 years.","30 years healthcare; previously VP Field Clinical Affairs at Abbott and Sr. VP/GM at St. Jude Medical.","Company plans national rollout of PURE EP system; 75 physicians performed 2150+ patient cases.","Clinical study showed 93% consensus and 75% improvement in intracardiac signal quality with PURE EP."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-22-000308","json":"https://secwatch.observer/filing/0001185185-22-000308.json","markdown":"https://secwatch.observer/filing/0001185185-22-000308.md","text":"https://secwatch.observer/filing/0001185185-22-000308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1530766/000118518522000308/0001185185-22-000308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1530766/000118518522000308/biosig20220318_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T20:55:40.837142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84e244fe85","claim":"John Sieckhaus was appointed as Chief Operating Officer at Streamex Corp..","evidence_excerpt":"On March 16, 2022, the Board of Directors (the “ Board ”) of BioSig Technologies, Inc. (the “ Company ”) appointed Mr. John Sieckhaus as the Chief Operating Officer of the Company, whose employment commenced on March 21, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1530766/000118518522000308/0001185185-22-000308-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}